These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21569313)

  • 1. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole.
    Heading RC; Mönnikes H; Tholen A; Schmitt H
    BMC Gastroenterol; 2011 May; 11():52. PubMed ID: 21569313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients.
    Goh KL; Choi KD; Choi MG; Hsieh TY; Jung HY; Lien HC; Menon J; Mesenas S; Park H; Sheu BS; Wu JC
    BMC Gastroenterol; 2014 Sep; 14():156. PubMed ID: 25200403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro-oesophageal reflux disease: a randomized, double-blind, controlled, multicentre trial.
    Hein J
    Clin Drug Investig; 2011; 31(9):655-64. PubMed ID: 21819161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial.
    Mönnikes H; Schwan T; van Rensburg C; Straszak A; Theek C; Lühmann R; Sander P; Tholen A
    BMC Gastroenterol; 2013 Oct; 13():145. PubMed ID: 24083350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease.
    Mönnikes H; Heading RC; Schmitt H; Doerfler H
    World J Gastroenterol; 2011 Jul; 17(27):3235-41. PubMed ID: 21912473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease.
    Mönnikes H; Schwan T; van Rensburg C; Straszak A; Theek C; Sander P; Lühmann R
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1279-89. PubMed ID: 22486552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease.
    Cheong JH; Kim GH; Lee BE; Choi MK; Moon JY; Ryu DY; Kim DU; Song GA
    Scand J Gastroenterol; 2011 Jul; 46(7-8):789-96. PubMed ID: 21615222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.
    Thomson AB
    Clin Drug Investig; 2007; 27(10):663-72. PubMed ID: 17803341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study.
    Hoogendoorn RJ; Groeneveld L; Kwee JA
    Clin Drug Investig; 2009; 29(12):803-10. PubMed ID: 19888786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
    Moraes-Filho JP; Pedroso M; Quigley EM;
    Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease.
    Zerbib F; Belhocine K; Simon M; Capdepont M; Mion F; Bruley des Varannes S; Galmiche JP
    Gut; 2012 Apr; 61(4):501-6. PubMed ID: 21997546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease.
    Scholten T; Teutsch I; Bohuschke M; Gatz G
    Clin Drug Investig; 2007; 27(4):287-96. PubMed ID: 17358101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error.
    van der Velden AW; de Wit NJ; Quartero AO; Grobbee DE; Numans ME
    Digestion; 2013; 87(2):85-90. PubMed ID: 23364219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease.
    Niu XP; Yu BP; Wang YD; Han Z; Liu SF; He CY; Zhang GZ; Wu WC
    World J Gastroenterol; 2013 May; 19(20):3124-9. PubMed ID: 23716993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease.
    van Rensburg CJ; Bardhan KD
    Eur J Gastroenterol Hepatol; 2001 Aug; 13(8):909-14. PubMed ID: 11507354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease.
    Plein K; Hotz J; Wurzer H; Fumagalli I; Lühmann R; Schneider A
    Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):425-32. PubMed ID: 10783996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
    Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
    J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.
    Nojkov B; Rubenstein JH; Adlis SA; Shaw MJ; Saad R; Rai J; Weinman B; Chey WD
    Aliment Pharmacol Ther; 2008 Mar; 27(6):473-82. PubMed ID: 18194508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study.
    Remes-Troche JM; Sobrino-Cossío S; Soto-Pérez JC; Teramoto-Matsubara O; Morales-Arámbula M; Orozco-Gamiz A; Tamayo de la Cuesta JL; Mateos G
    Clin Drug Investig; 2014 Feb; 34(2):83-93. PubMed ID: 24347282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study.
    Wilder-Smith C; Backlund A; Eckerwall G; Lind T; Fjellman M; Röhss K
    Clin Drug Investig; 2008; 28(6):333-43. PubMed ID: 18479175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.